Safety of long acting β2-agonists in the management of asthma;β2-sympathomimetika: Gefahren in der asthmatherapie? Lehren aus der SMART1-Studie - Eine stellungnahme der Deutschen atemwegsliga

Deutsche Medizinische Wochenschrift

Volumn 132, Issue 1-2, 2007, Pages 33-39

  Gillissen, A ^a,b   Berdel, D ^c   Buhl, R ^d   Criee C P ^e   Kardos, P ^f   Magnussen, H ^g   Rabe, K F ^h   Rolke, M ⁱ   Vogelmeier, C ^j   Worth, H ^k   Virchow, J C ^l  

^a Institutsangaben Auf Seite 38 ^*  (Germany)

^b Robert Koch Klinik   (Germany)

^c Marien Hospital   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e Sleep Laboratory   (Germany)

^f Maingau Krankenhaus   (Germany)

^g KRANKENHAUS GROSSHANSDORF   (Germany)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ Pneumologische Gemeinschaftspraxis   (Germany)

^j PHILIPPS UNIVERSITY MARBURG   (Germany)

^k KLINIKUM FÜRTH   (Germany)

^l ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

more..

Author keywords

2 agonists; Asthma; Corticosteroids; Fomoterol; Mortality; Salmeterol; Therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; SALMETEROL; ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ASTHMA; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; DRUG SAFETY; HUMAN; IN VIVO STUDY; MORTALITY; REVIEW; RISK FACTOR; AFRICAN AMERICAN; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG POTENTIATION; ETHNOLOGY; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADRENERGIC BETA-AGONISTS; AFRICAN AMERICANS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; SYMPATHOMIMETICS; UNITED STATES;

EID: 33947181468     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-959286     Document Type: Review

References (42)

1. Anderson HR, Aytes JG, Sturdy PM et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330: 117-119
2. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ). Nationale Versorgungsleitlinie Asthma. Dt Ärztebl 2005; 40: B2307-B2311
3. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152: 838-860
4. Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma control (GOAL) study. Am J Respir Crit Care Med 2004; 170: 836-844
5. Bisgaard H. Long-acting β2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000; 29: 221-234
6. Bisgaard H. Effect of long-acting beta2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003; 36: 391-398
7. Bisgaard H, Szefler S. Long-acting beta2-agonists and paediatric asthma. Lancet 2006; 367: 286-288
8. British Thoracic Society. The british guidelines on asthma management. Asthma in adults and schoolchildren. Thorax 2003; 58: 1-94
9. Buhl R, Berdel D, Criee C-P et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Pneumologie 2006; 60: 139-183
10. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306: 1034-1037
11. Fahy JV, Boushey HA. Controversies involving inhaled beta-agonists and inhaled corticosterids in the treatment of asthma. Clin Chest Med 1995; 16: 715-733
12. Gillissen A, Jaworska M, Schärling B, van Zwoll D, Schultze-Werninghaus G. β2-agonists have antioxidant function in vitro (part I). Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Respiration 1996; 64: 16-21
13. GOLD Executive Committee. Global initiative for chronic obstructive lung disease. wwwgoldcopdcom, 2005
14. Kroegel C, Buhl R, Gillissen A, Petro W. Asthma bronchiale versus chronisch-obstruktive Lungenkrankheit (COPD). Von der Pathogenese zur Differentialdiagnostik und Differentialtherapie. Dtsch Med Wochenschr 2005; 130: 812-818
15. Lurie P, Wolfe SM. Misleading data analysis in salmeterol (SMART) study. Lancet 2005; 366: 1261-1262
16. Mann M, Chowdhury BA, Sullivan EJ, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124: 70-74
17. Maris NA, de Vos AF, Dessing MC et al. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005; 172: 878-884
18. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005; 353: 2637-2639
19. McCoy L, Redelings M, Sorvillo F, Simon P. A multiple cause-of-death analysis of asthma mortality in the United States, 1990-2001. J Asthma 2005; 42: 757-763
20. National Institute for Clinical Excellence. Chronic obstructive pulmonary disase. National clinical guideline on management of chronich obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59: 1-232
21. National Institutes of Health (Hrsg). Global strategy for asthma management and prevention NHLBI/WHO Workshop report. Bethesda, USA, U.S. Department of Health and Human Services (www.ginasthma.com). 2005: 1-176
22. Nelson HS. Is there a problem with inhalaed long-acting β-adrenergic agonists? J Allergy Clin Immunol 2006; 117: 3-16
23. Nelson HS, Weiss ST, Bleeker ER, Yancey SW, Dorinsky PM. The salmeterol mulicenter asthma research trial. A comparision of usal pharmacotherapy for asthma or usal pharmacotherapy plus salmeterol. Chest 2006; 129: 15-26
24. O'Byrne PM, Ädelroth E. β2 déjà vu. Chest 2006; 129: 3-5
25. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta2-agonists in asthma. N Engl J Med 1992; 328: 665-666
26. O'Connor RD, Standorf R, Crim C et al. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control. Ann Allergy Asthma Immunol 2004; 93: 581-588
27. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. The arginine-16 beta 2 adrenoceptor genotype predisposis to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61: 940-944
28. Pauwels RA, Löfdahl C-G, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411
29. Petermann W, Mutschler E. Fixkombination aus inhalativen Steroid und langwirkendem beta2-Agonisten. Eine wichtige Option in der Therapie des persistierenden Asthma. Dtsch Med Wochenschr 2004; 129: 210-214
30. Rickard KA. Misleading data analysis in salmeterol (SMART) study: GlaxoSmithkline's reply. Lancet 2005; 366: 1262-1263
31. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-Analysis: Effect of long-acting β-agonists on severe-asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904-912
32. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: Anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med 2006; 21: 1011-1019
33. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular β2-agnoist use in patients with asthma. Ann Intern Med 2004; 140: 802-813
34. Sears M. Consequences of long-term inflammation. The natural history of asthma. Clin Chest Med 2000; 21: 315-329
35. Sears MR, Taylor DR, Print CG et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396
36. Suissa S, Ernst P, Benayoun S, Baltzan M, Sci B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-336
37. Suissa S, Hemmelgarn B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154: 1598-1602
38. Tal A, Simon G, Vermeulen JH et al. Budesonid/Formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34: 342-350
39. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998; 158: 213-219
40. Wechsler ME, Israel E. How pharmacogenomics will play a role in th emanagement of asthma. Am J Respir Crit Care Med 2005; 172: 12-18
41. Wolfe J, LaForce CF, Sokol W, Orevillo C, Till D. Formoterol, 24 μg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 μg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129: 27-38
42. Worth H, Buhl R, Cegla U et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem(COPD). Pneumologie 2002; 56: 704-738